期刊文献+

帕金森病患者血清klk6、HSP70检测的临床意义研究 被引量:2

Study of Clinical Significance of Serum Klk6 and HSP70 Detection in Patients with Parkinson's Disease
原文传递
导出
摘要 目的:探讨帕金森病(PD)患者血清激肽释放酶6(klk6)、热休克蛋白70(HSP70)水平与病情严重程度以及PD轻度认知障碍(PD-MCI)的关系。方法:选择2021年2月至2022年2月徐州医科大学附属医院收治的165例PD患者(PD组),根据修订的Hoehn-Yahr分级将PD患者分为早期组(1.0~2.5级,59例)、中期组(3.0级,65例)和晚期组(4.0~5.0级,41例),根据是否存在PD-MCI将PD患者分为PD-MCI组(66例)和非PD-MCI组(99例),另选择同期72例于我院门诊体检的健康志愿者为对照组。检测血清klk6、HSP70水平,比较不同分组血清klk6、HSP70水平差异,多因素Logistic回归分析影响PD患者发生PD-MCI的因素。结果:PD组血清klk6水平高于对照组(P<0.05),HSP70水平低于对照组(P<0.05),晚期组血清klk6水平高于早期组和中期组,且中期组血清klk6水平均高于早期组(P<0.05),晚期组血清HSP70水平低于早期组和中期组,且中期组血清HSP70水平低于早期组(P<0.05);PD-MCI组血清klk6水平高于非PD-MCI组(P<0.05),HSP70水平低于非PD-MCI组(P<0.05)。多因素Logistic回归分析结果显示年龄偏高、修订的Hoehn-Yahr分级晚期、高水平klk6是PD患者发生PD-MCI的危险因素(P<0.05),高水平HSP70是PD患者发生PD-MCI的保护因素(P<0.05)。结论:PD患者血清klk6水平增高,HSP70水平降低与修订的Hoehn-Yahr分级增加以及PD-MCI有关,检测血清klk6、HSP70水平有助于评估PD病情以及PD-MCI风险。 Objective:To explore the relationship between serum levels of kallikrein 6(klk6)and heat shock protein 70(HSP70)in patients with Parkinson's disease(PD)and the severity of the condition,as well as mild cognitive impairment in PD(PD-MCI).Methods:165 patients with PD(PD group)who were admitted to Affiliated Hospital of Xuzhou Medical University from February 2021 to Febru-ary 2022 were selected,the patients with PD were divided into early stage group(stage 1.0 to 2.5,59 cases),mid stage group(stage 3.0,65 cases)and late stage group(stage 4.0 to 5.0,41 cases)according to the revised Hoehn-Yahr stage,the patients with PD were divided into PD-MCI group(66 cases)and non PD-MCI group(99 cases)based on the presence or absence of PD-MCI,and another 72 healthy volunteers who underwent physical examinations in our outpatient department during the same period were selected as control group.The serum levels of klk6 and HSP70 were detected,the differences of serum levels of klk6 and HSP70 among different groups were com-pared,and the factors affected the occurrence of PD-MCI in patients with PD was analysed by multivariate Logistic regression.Results:Serum klk6 level in PD group was higher than that in control group(P<0.05),serum HSP70 level was lower than that in control group(P<0.05),serum klk6 level in late stage group was higher than that in early and mid stage groups,and serum klk6 level in mid stage group was higher than that in early stage group(P<0.05),serum HSP70 level in late stage group was lower than that in early and mid stage groups.The serum HSP70 level in the mid stage group was lower than that in the early stage group(P<0.05).The serum klk6 level in PD-MCI group was higher than that in non-PD-MCI group(P<0.05),and the serum HSP70 level in PD-MCI group was lower than that in non-PD-MCI group(P<0.05).Multivariate Logistic regression analysis showed that older age,late modified Hoehn-Yahr grade and high level of klk6 were risk factors for PD-MCI in PD patients(P<0.05),and high level of HSP70 was protective factor for PD-MCI in PD patients(P<0.05).Conclusion:The increase of serum klk6 level and the decrease of HSP70 level in PD patients are related to the increase of modified Hoehn-Yahr grade and PD-MCI.The detection of serum klk6 and HSP70 levels is helpful to evaluate the disease condition of PD and the risk of PD-MCI.
作者 王镜森 郑智方 屈小莹 杜楠 张尊胜 WANG Jing-sen;ZHENG Zhi-fang;QU Xiao-ying;DU Nan;ZHANG Zun-sheng(Graduate School of Xuzhou Medical University,Xuzhou,Jiangsu,221002,China;Department of Internal Medicine-Neurology,Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,221002,China)
出处 《现代生物医学进展》 CAS 2023年第19期3744-3748,共5页 Progress in Modern Biomedicine
基金 江苏省"六大人才高峰"资助项目(2015-WSN-064)。
关键词 帕金森病 KLK6 HSP70 病情严重程度 认知障碍 Parkinson's disease klk6 HSP70 Severity of condition Cognitive impairment
  • 相关文献

参考文献6

二级参考文献60

  • 1刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量:790
  • 2Chaudhuri KR, Healy DG, Schapira AH, et al. Non-motor symptoms of Parkinson's disease: diagnosis and management [J]. Lancet Neurol, 2006, 5(3): 235-245.
  • 3Petersen RC. Mild cognitive impairment as a diagnostic entity [J]. J Intern Med, 2004, 256(3): 183-194.
  • 4Poletti M, Frosini D, Ceravolo R, et al. Mild cognitive impairment in de novo Parkinson's disease according to movement disorder guidelines[J]. Mov Disord, 2012, 27(13): 1706-1707.
  • 5Poletti M, Frosini D, Pagni C, et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease [J]. J Neurol Neurosurg Psychiatry, 2012, 83 (6): 601-606.
  • 6Hely MA, Reid WG, Adena MA, et al. The Sydney multieenter study of Parkinson's disease: the inevitability of dementia at 20 years [J]. Mov Disord, 2008, 23(6): 837-844.
  • 7Rosenthal E, Brennan L, Xie S, et al. Association between cognition and function in patients with Parkinson's disease with and without dementia[J]. Mov Disord, 2010, 25(9): 1170-1176.
  • 8Vossius C, Larsen JP, Janvin C, et al. The economic impact of cognitive impairment in Parkinson's disease[J]. Mov Disord, 2011, 26 (8): 1541-1544.
  • 9Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD [J]. Neurology, 2002, 59 (11): 1708-1713.
  • 10Pedersen KF, Larsen JP, Tysnes OB, et al. Prognosis of mild cognitive impairment in early Parkinson's disease: the Norwegian ParkWest study[J]. JAMA Neurol, 2013, 70(5): 580-586.

共引文献773

同被引文献14

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部